Akira Fukutomi

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet · 2016 · 1.1K citations

Surgical Oncology, Oncology, Pancreatic Cancer +6

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al. · British Journal of Cancer · 2010 · 733 citations · Full text

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2013 · 624 citations

Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer

Tomoki Ebata, Satoshi Hirano, Masaru Konishi et al. · British journal of surgery · 2018 · 378 citations

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 320 citations

S-1 Versus Gemcitabine, Gastrointestinal Oncology, Medicine +7